Navigation Links
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Date:5/7/2009

be presented at the 2009 APS meeting:

Thursday, May 7: 4:15-5:45 PM

Poster 301: Efficacy and Safety of Tapentadol ER for Chronic Low Back Pain: Results of a Randomized, Double-blind, Placebo- and Active-controlled Phase 3 Study; Primary investigator: Robert Buynak, M.D.

Poster 293: Efficacy, Safety, and Gastrointestinal Tolerability of Tapentadol ER in a Randomized, Double-blind, Placebo- and Active-controlled Phase III Study of Patients With Chronic Low Back Pain; Primary investigator: Robert Buynak, M.D.

Friday, May 8: 4:00-5:30 PM

Poster 306: A Randomized, Double-blind, Placebo- and Active-controlled Phase 3 Study of Tapentadol ER for Chronic Low Back Pain: Analysis of Efficacy Endpoint Sensitivity; Primary investigator: Mila Etropolski, M.D.

J&JPRD and Ortho-McNeil-Janssen Pharmaceuticals, Inc. are wholly owned subsidiaries of Johnson & Johnson.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) is a wholly owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com/.

PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a major health care company in the United States dedicated to the needs of primary car
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
2. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
6. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
7. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
8. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
9. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
10. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
(Date:5/28/2015)... -- This report analyzes the worldwide markets for Intraocular Lenses ... Standard Intraocular Lenses, and Premium Intraocular Lenses. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced data from a recently ... oral dose formulation for LX4211, a dual inhibitor of ... Results from the study demonstrated that administration of ...
... Jan. 5, 2011 The pharmaceutical industry,s steep ... strategy and development executives to uncover opportunities for ... combination therapies with branded products to extend patent ... products can extend a therapeutic advantage and become ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... giving patients a long-lasting impression on what modern dentistry ... VisitandCare.com is on a mission to revolutionize the perception ... with a high-class Wellness & Spa. , The ... world’s most successful medical tourism agencies and ...
(Date:5/29/2015)... MN (PRWEB) May 29, 2015 As ... Patio and Metro series outdoor saunas have increased in ... landscaping projects, and work at summer cottages. While ... piqued interest in summer projects a few weeks earlier ... suburban communities with smaller lot sizes tend to prefer ...
(Date:5/29/2015)... 29, 2015 Vulvodynia is defined as ... significant physical, sexual, and psychological distress. Women’s ... Vulvodynia. The actual diagnosis is often made on the ... realize that this problem can be very troublesome to ... these symptoms, they need to schedule and appointment with ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... Liberator Medical,Holdings, Inc. (OTC Bulletin Board: LBMH.OB) reported ... 2007 sales, which is thus far,the highest sales ... the Company,s ongoing continuous targeted advertising effort., ... our November,sales, we believe that in our first ...
... near crowded roadways face more than 50% risk of breathing ... Children with asthma who are exposed to traffic pollution are ... says a study that looked at children in the Mexican ... United States. , "Major cities along the northern and ...
... 13 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... two skilled,nursing facilities in California and one assisted ... of approximately $12.8 million., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... part of its ongoing,global campaign to lower drug prices ... worldwide, AIDS Healthcare Foundation,(AHF) today responded to a modest ... Cipla, on three of its antiretroviral drugs to,fight HIV/AIDS. ... AHF-led,advocacy campaign aimed at pressuring Cipla to lower its ...
... in patients battling stomach cancer , , THURSDAY, Dec. 13 ... sunitinib (Sutent), which fights stomach tumors, can also create ... , All patients taking sunitinib, but especially those ... and treatment for high blood pressure and other signs ...
... Pro Bowler and TODAY,correspondent Tiki Barber spoke publicly for ... affects such a wide range of people in,different circumstances ... he told Meredith Vieira this morning on TODAY., ... founding,member and president, also appeared on TODAY to discuss ...
Cached Medicine News:Health News:Liberator Medical Supply Exceeds Projected November Sales 2Health News: Traffic Pollution Hurts Asthmatic Kids' Lungs 2Health News:The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 3Health News:New Cancer Drug Tied to Heart Problems 2Health News:New Cancer Drug Tied to Heart Problems 3Health News:New Cancer Drug Tied to Heart Problems 4Health News:Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show 2
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: